Skip to main content

FDA Approves Metvixia

FDA Approves Metvixia for Actinic Keratosis

Methyl aminolevulinate is a novel, non-invasive treatment which combines the local application of cream, selectively absorbed into abnormal cells, and illumination with a proprietary red light source (CureLight/Aktilite) to activate the drug for the photodynamic treatment of sun-induced pre-cancerous skin lesions (actinic keratosis) .

Related articles

Metvixia (methyl aminolevulinate hydrochloride) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.